Speaking at the company’s second quarter earnings call on the recent regulatory changes on the healthcare sector, Reddy said “We need to continue to sensitise them (the government). They are looking at it in terms of the costs of cancer medicines or consumables. But it’s not a cost-plus model. It’s a model where the entire service is delivered and the costs are attached to it."